Testing a new targeted medication for advanced melanoma with a specific genetic mutation

Plain-English translation of NCT07237100 on ClinicalTrials.gov ↗ · Source last updated November 2025 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a medication called to see if it can help patients with advanced melanoma that has spread and carries an NF1 genetic mutation. works by blocking specific pathways inside cancer cells that make them grow too quickly. Unlike traditional chemotherapy, this medication targets cancer cells more directly, which may mean fewer side effects on healthy cells.

Most patients with advanced melanoma are first treated with immunotherapy drugs (checkpoint inhibitors), but some tumors stop responding or patients cannot tolerate these treatments. This trial explores whether this medication offers a new option for people whose cancer is still growing despite previous treatments.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced melanoma that has spread or cannot be surgically removed
your melanoma has been confirmed to have an NF1 genetic mutation through testing at a certified laboratory
your cancer is still growing despite previous treatment with at least some checkpoint inhibitor immunotherapies (or you could not receive them due to other health conditions)
you are at least 18 years old and in relatively good overall health
you have measurable tumors that can be tracked on imaging scans
your blood counts, kidney function, liver function, and heart function are adequate based on recent blood tests and heart imaging

You likely don't qualify if…

you have not been previously treated with checkpoint inhibitor immunotherapy drugs (unless your doctors determined these were not safe for you)
you have very low blood cell counts, severely impaired kidney or liver function, or recent heart problems
you are pregnant, breastfeeding, or unwilling to use effective birth control during the study
your melanoma does not carry an NF1 mutation, or the mutation status is uncertain

What participation looks like

You would take the medication by mouth twice daily in 28-day cycles, with each cycle followed by a break before the next one begins. You would have regular clinic visits and blood tests to monitor how well the medication is working and to check for any side effects. The study will continue as long as your cancer is not growing worse and you are tolerating the medication well, with the goal of determining whether this treatment is safe and effective for your type of melanoma.

AI-generated summary from trial data · Jun 7, 2026 · Not medical advice

Trial locations(1 site)

United States

California Pacific Medical Center - Sutter Health, San Francisco, California